Kairos Pharma Stock Forecast

Stock Price Forecast

The 2 analysts with 12-month price forecasts for Kairos Pharma stock have an average target of 8.00, with a low estimate of 4.00 and a high estimate of 12. The average target predicts an increase of 2,185.71% from the current stock price of 0.35.

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$4.00	$8.00	$12	$12
Change	+1042.9%	+2185.7%	+3328.6%	+3328.6%

* Price targets were last updated on May 14, 2026.

Analyst Ratings

The average analyst rating for Kairos Pharma stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Sep '25	Oct '25	Nov '25	Mar '26	Apr '26	May '26
Strong Buy	2	2	2	2	2	1
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	3	3	3	3	3	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Joseph Pantginis H.C. Wainwright	H.C. Wainwright	Buy Reiterates $12	Buy	Reiterates	$12	+3,328.57%	May 14, 2026
Jason McCarthy Maxim Group	Maxim Group	Buy Maintains $4	Buy	Maintains	$4	+1,042.86%	Mar 9, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-0.37

from -0.30

EPS Next Year

-0.67

from -0.37

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	-	-	-	-	-	-	-
Revenue Growth	-	-	-	-	-	-	-
EPS	-0.23	-0.10	-0.17	-0.23	-0.30	-0.37	-0.67
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	1	1

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	n/a	n/a
Avg	n/a	n/a
Low	n/a	n/a

Revenue Growth

Revenue Growth	2027	2028
High	-	-
Avg	-	-
Low	-	-

EPS Forecast

EPS	2026	2027
High	-	-
Avg	-0.37	-0.67
Low	-	-

EPS Growth

EPS Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.